COEXPRESSION OF IMMUNE CHECKPOINT MARKERS PD-1, PD-L1, TIM-3, AND LAG-3 IN CIRCULATING AND TUMOR-INFILTRATING T CELL POPULATIONS IN CERVICAL CANCER PATIENTS
- 作者: Kurmyshkina O.1, Bogdanova A.1,2, Kovchur P.1, Volkova T.1
-
隶属关系:
- Petrozavodsk State University
- Institute of Biology of the Karelian Research Centre of the RAS
- 期: 卷 22, 编号 4 (2019)
- 页面: 1491-1493
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/119603
- DOI: https://doi.org/10.31857/S102872210007068-9
- ID: 119603
如何引用文章
全文:
详细
作者简介
O. Kurmyshkina
Petrozavodsk State University
编辑信件的主要联系方式.
Email: fake@neicon.ru
PhD, seniorresearcher, Laboratory of Molecular Genetics of Innate Immunity, Institute of High-Tech Biomedicine,
Petrozavodsk
俄罗斯联邦A. Bogdanova
Petrozavodsk State University;Institute of Biology of the Karelian Research Centre of the RAS
Email: fake@neicon.ru
PhD student, Laboratory for Environmental Biochemistry,
Petrozavodsk
俄罗斯联邦P. Kovchur
Petrozavodsk State University
Email: fake@neicon.ru
MD-PhD, professor of the Department of hospital surgery, ENT diseases, ophthalmology, dentistry, oncology, urology, Institute of Medicine,
Petrozavodsk
俄罗斯联邦T. Volkova
Petrozavodsk State University
Email: VolkovaTO@yandex.ru
PhD, professor of the Department ofbiomedical chemistry, immunology and laboratory diagnostics, Institute of Medicine; director of the Institute of High-Tech Biomedicine,
Petrozavodsk
俄罗斯联邦参考
- Wang HF, Wang SS, Tang YJ, Chen Y, Zheng M, Tang YL, Liang XH. The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer.Front Immunol. 2019, 10, 653.
- Liu Y, Wu L, Tong R, Yang F, Yin L, Li M, You L, Xue J, Lu Y. PD-1/PD-L1 Inhibitors in Cervical Cancer.Front Pharmacol. 2019, 10, 65.
- Heeren AM, Rotman J, Stam AGM, Pocorni N, Gassama AA, Samuels S, Bleeker MCG, Mom CH, Zij lmans HJMAA, Kenter GG, Jordanova ES, de Gruij l TD. Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. J Immunother Cancer. 2019, 7, 43.
